Johnson & Johnson’s portfolio now includes treatment options for patients with rheumatoid arthritis, axial spondylarthritis, and polyarticular juvenile idiopathic arthritis.
High Wycombe, UK, 17 October 2024 - Johnson & Johnson (J&J) announced today that it has now assumed all sales, marketing and distribution responsibility for Remicade® (infliximab) and Simponi® (golimumab) in the United Kingdom (UK). Infliximab is an anti‑inflammatory medicine indicated for the treatment of rheumatoid arthritis (RA), Crohn’s disease (CD), paediatric CD, ulcerative colitis (UC), paediatric UC, radiographic axial spondyloarthritis (ankylosing spondylitis), psoriatic arthritis (PsA), and psoriasis.1 Golimumab is an anti-inflammatory medicine indicated for the treatment of RA, polyarticular juvenile idiopathic arthritis, PsA, radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, and UC.2 3
For more than 25 years, infliximab, and, for more than a decade, golimumab, have helped millions of people managing life-altering inflammatory diseases and remain significant options in the treatment paradigm for these people in the UK.2,4 The addition of infliximab and golimumab into J&J’s established immunology portfolio represents a significant milestone in the company’s ongoing commitment to provide trusted and reliable healthcare solutions for patients in need.
Merck Sharp & Dohme (UK) Limited (MSD) ceased the commercialisation of infliximab and golimumab and transferred the responsibility of Local Representative to Janssen-Cilag Ltd (a Johnson & Johnson Company) who assumed commercial activities from 1 October 2024. J&J collaborated closely with MSD during the transition process to prevent any impact to the lives of patients using infliximab and golimumab.
#ENDS#
About Remicade (infliximab)
Infliximab 100 mg is a chimeric human-murine IgG1 monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of tumour necrosis factor alpha (TNFα) and inhibits its functional activity. TNFα is involved in inflammatory processes of the body so blocking it can reduce the inflammation in the body. Infliximab is usually used when other medicines or treatments have failed, in adults with the following diseases: rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Infliximab is also used in patients aged between 6 and 17 years with severe, active Crohn’s disease or severely active ulcerative colitis, when they have not responded to or cannot take other medicines or treatments.1
About Simponi (golimumab)
Golimumab 50 mg / 100 mg is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNFα, which prevents the binding of TNFα to its receptors. TNFα is involved in inflammatory processes of the body so blocking it can reduce the inflammation in the body. Golimumab is indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis, and ulcerative colitis.2, 3
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.janssen.com/UK/johnson-johnson-innovative-medicine. You can also follow us on LinkedIn.
© Janssen-Cilag Limited, a Johnson & Johnson Company. All rights reserved.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product transition of Remicade (infliximab) and Simponi (golimumab). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov/, http://www.jnj.com/ or on request from Johnson & Johnson. None of Janssen Biotech, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
Media contact: |
Investor contact: |